Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Johanne M Holst
  • Trine L Plesner, i Department of Pathology , Rigshospitalet , Copenhagen , Denmark.
  • ,
  • Martin B Pedersen
  • Henrik Frederiksen, Department of Hematology, Odense University Hospital, Odense, Denmark.
  • ,
  • Michael B Møller, Haematology-Pathology Research Laboratory, Odense University Hospital, Denmark; Department of Pathology, Odense University Hospital, Denmark.
  • ,
  • Michael R Clausen
  • ,
  • Marcus C Hansen
  • Stephen Jacques Hamilton-Dutoit
  • Peter Nørgaard, Department of Pathology, Herlev Hospital, University of Copenhagen, DK-2730 Herlev, Denmark. alha@herlevhosp.kbhamt.dk
  • ,
  • Preben Johansen, Aalborg Universitet
  • ,
  • Tobias Ramm Eberlein
  • ,
  • Bo K Mortensen, Department of Hematology, Herlev Hospital, Herlev, Denmark.
  • ,
  • Gustav Mathiasen, Department of Hematology, Roskilde Hospital, Roskilde, Denmark
  • ,
  • Andreas Øvlisen, Aalborg Universitet
  • ,
  • Rui Wang, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York City, USA.
  • ,
  • Chao Wang, Department of Pathology, City of Hope Medical Center, Duarte, USA.
  • ,
  • Weiwei Zhang, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
  • ,
  • Hans Beier Ommen
  • Jesper Stentoft
  • Maja Ludvigsen
  • Wayne Tam, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York City, USA.
  • ,
  • Wing C Chan, Department of Pathology, City of Hope Medical Center, Duarte, USA.
  • ,
  • Giorgio Inghirami, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York City, USA.
  • ,
  • Francesco d'Amore

Myeloid and lymphoid malignancies are postulated to have distinct pathogenetic mechanisms. The recent observation that patients with a myeloproliferative neoplasm have an increased risk of developing lymphoproliferative malignancy has challenged this assumption. We collected a nationwide cohort of patients with both malignancies. Patients diagnosed in 1990-2015 were identified through the national Danish Pathology Registry. We identified 599 patients with myeloproliferative neoplasm and a concomitant or subsequent diagnosis of lymphoma. Histopathological review of the diagnostic samples from each patient led to a final cohort of 97 individuals with confirmed dual diagnoses of myeloproliferative neoplasm and lymphoma. The age range at diagnosis was 19-94 years (median: 71 years). To avoid the inclusion of cases of therapy-induced myeloproliferative neoplasm occurring in patients previously treated for lymphoma, only patients with myeloproliferative neoplasm diagnosed unequivocally before the development of lymphoma were included. The average time interval between the diagnoses of the two malignancies was 1.5 years. In the majority of patients (90%) both diagnoses were established within 5 years from each other. Among the lymphoma entities, the frequency of peripheral T-cell lymphomas was markedly increased. Interestingly, all but one of the T-cell lymphomas were of angioimmunoblastic type. These findings suggest that myeloproliferative neoplasm and lymphoproliferative malignancy developing in the same patient may have common pathogenetic events, possibly already at progenitor level. We believe that the molecular characterization of the newly developed biorepository will help to highlight the mechanisms driving the genesis and clonal evolution of these hematopoietic malignancies.

OriginalsprogEngelsk
TidsskriftHaematologica
Vol/bind105
Nummer10
Sider (fra-til)2432-2439
Antal sider8
ISSN0390-6078
DOI
StatusUdgivet - okt. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 172941525